Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% Equity-to-Asset is 0.61 as of Dec. 2025, which is 27% below its 10-year median of 0.84. The stock has 8 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Resonance Health ranks better than 64.28% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Resonance Health's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$10.94 Mil. Resonance Health's Total Assets for the quarter that ended in Dec. 2025 was A$17.96 Mil.
Therefore, Resonance Health's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.61.
The historical rank and industry rank for Resonance Health's Equity-to-Asset or its related term are showing as below:
ASX:RHT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46 Med: 0.84 Max: 0.96
Current: 0.61
During the past 13 years, the highest Equity to Asset Ratio of Resonance Health was 0.96. The lowest was 0.46. And the median was 0.84.
ASX:RHT's Equity-to-Asset is ranked better than 64.28% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 0.48
vs ASX:RHT: 0.61
Resonance Health (ASX:RHT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Resonance Health Equity-to-Asset Related Terms
Resonance Health Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Resonance Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, HQY: Equity-to-Asset Comparison
For the Health Information Services subindustry, Resonance Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Resonance Health's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Resonance Health's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Equity-to-Asset of 0.61 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Resonance Health and its competitors. This is 27% below median its historical median of 0.84. Over the past decade, Resonance Health's Equity-to-Asset has ranged from 0.46 to 0.96. According to the industry distribution chart, Resonance Health ranks #244 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 35.7%.
Is Resonance Health's Equity-to-Asset too high?
Resonance Health's current Equity-to-Asset of 0.61 is 27% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 0.96. The Healthcare Providers & Services industry median Equity-to-Asset is 0.48. Resonance Health's value of 0.61 is 27.1% above this industry median. Based on the distribution chart, Resonance Health ranks #244 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's Equity-to-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #244 out of 683 companies for Equity-to-Asset. This puts Resonance Health in the upper half of its industry. The industry median Equity-to-Asset is 0.48. Resonance Health's value of 0.61 is 27.1% above this benchmark. Historically, Resonance Health's own Equity-to-Asset has ranged from 0.46 to 0.96 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.48, Resonance Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Equity-to-Asset of 0.61 is 27.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Equity-to-Asset is 0.61, which is 27% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current Equity-to-Asset is 0.61, which is 27% below median its 10-year median of 0.84 and 27.1% above the Healthcare Providers & Services industry median of 0.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Equity-to-Asset is 0.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
